VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
Novel conditionally active T cell engagers sourced from proprietary BiTAC® platform are at the basis of advanced partnering initiatives and development activitiesZURICH, SWITZERLAND – July 6, 2026 -- VERAXA Biotech AG NASDAQ:VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, t…